Trial Profile
Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Carboplatin (Primary) ; Epirubicin (Primary) ; Fluorouracil (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms MEMORI
- 22 Nov 2023 Status changed from active, no longer recruiting to completed.
- 21 Sep 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 21 Sep 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.